NO20084832L - Pyrimidinderivater som P13K-inhibitorer - Google Patents
Pyrimidinderivater som P13K-inhibitorerInfo
- Publication number
- NO20084832L NO20084832L NO20084832A NO20084832A NO20084832L NO 20084832 L NO20084832 L NO 20084832L NO 20084832 A NO20084832 A NO 20084832A NO 20084832 A NO20084832 A NO 20084832A NO 20084832 L NO20084832 L NO 20084832L
- Authority
- NO
- Norway
- Prior art keywords
- group
- alk
- unsubstituted
- alkyl
- substituted
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017701 Endocrine disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 102000038030 PI3Ks Human genes 0.000 abstract 1
- 108091007960 PI3Ks Proteins 0.000 abstract 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000006399 behavior Effects 0.000 abstract 1
- 230000003915 cell function Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
Tienopyrimidiner med formel (Ia) eller (Ib): hvori R1 er en gruppe med formel: R2 er H, halo eller C1-C6 alkyl; R3 er en indolgruppe som er usubstituert eller substituert; R4 og R5 danner, sammen med N-atomet som de er bundet til, en gruppe valgt fra piperazin, piperidin og pyrrolidin, hvis gruppe er usubstituert eller substituert med en eller flere grupper valgt fra C1-C6 alkyl, -S(O)2 R10 , -S(O)2-(alk)q-NR11R12, okso (=O), -alk-OR10 , -(alk)q-Het, en heterosyklylgruppe og -NR13R14; eller en av R4 og R5 er C1-C6 alkyl og den andre er en piperazin-, piperidin- eller pyrrolidingruppe, hvis gruppe er usubstituert eller substituert; R10 er H eller C1-C6 alkyl som er usubstituert; R11 og R12 er hver uavhengig valgt fra H og C1-C6 alkyl som er usubstituert, eller R11 og R12 danner, sammen med N-atomet som de er bundet til, en 5- eller 6-leddet mettet heterosyklisk gruppe; R13 og R14 er hver uavhengig valgt fra C1-C6 alkyl, -S(O)2 R10, alk-OR10, -(alk)q-Ph og -(alk)q-Het; Ph er fenyl; q er 0 eller 1; Het er en tiazol-, imidazol-, pyrrol-, pyridin- eller pyrimidingruppe, hvis gruppe er usubstituert eller substituert; og alk er C1-C6 alkylen; og de farmasøytisk akseptable saltene derav har aktivitet som inhibitorer av PI3K og kan således bli brukt for å behandle sykdommer og forstyrrelser som kommer som et resultat av abnorm cellevekst, -funksjon eller -oppførsel assosiert med PI3 kinase, spesielt p110 delta subtypen, sånn som immunforstyrrelser, kardiovaskulær sykdom, viral infeksjon, inflammasjon, metabolske/endokrine forstyrrelser og neurologiske forstyrrelser. Prosesser for å syntetisere forbindelsene er også beskrevet.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0608264A GB0608264D0 (en) | 2006-04-26 | 2006-04-26 | Pharmaceutical compounds |
| GB0608397A GB0608397D0 (en) | 2006-04-27 | 2006-04-27 | Pharmaceutical compounds |
| PCT/GB2007/001504 WO2007122410A1 (en) | 2006-04-26 | 2007-04-25 | Pyrimidine derivatives as pi3k inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20084832L true NO20084832L (no) | 2008-11-18 |
Family
ID=38110021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20084832A NO20084832L (no) | 2006-04-26 | 2008-11-18 | Pyrimidinderivater som P13K-inhibitorer |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8252792B2 (no) |
| EP (1) | EP2032582A1 (no) |
| JP (1) | JP5302186B2 (no) |
| KR (1) | KR20090021155A (no) |
| AU (1) | AU2007242594A1 (no) |
| BR (1) | BRPI0710866A2 (no) |
| CA (1) | CA2650196A1 (no) |
| CR (1) | CR10369A (no) |
| EC (1) | ECSP088867A (no) |
| IL (1) | IL194755A0 (no) |
| MA (1) | MA30360B1 (no) |
| MX (1) | MX2008013582A (no) |
| NO (1) | NO20084832L (no) |
| RU (1) | RU2008141356A (no) |
| WO (1) | WO2007122410A1 (no) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2041139T3 (pl) * | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
| BRPI0717907A2 (pt) | 2006-12-07 | 2013-11-05 | Genentech Inc | "composto, composição farmacêutica, métodos para tratar um câncer, para inbir ou modular a atividade da lipídeo quinase, processo para a produçãoo de uma composição farmacêutica, uso de um composto e kit" |
| AR064155A1 (es) | 2006-12-07 | 2009-03-18 | Piramed Ltd | Compuestos de inhibidores de fosfoinositido-3 quinasa y metodos de uso |
| EP2158207B1 (en) | 2007-06-12 | 2011-05-25 | F. Hoffmann-La Roche AG | Thiazoliopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase |
| CA2699202C (en) | 2007-09-12 | 2016-09-27 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| EP2207781B1 (en) | 2007-09-24 | 2012-11-28 | Genentech, Inc. | Thiazolopyrimidine p13k inhibitor compounds and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| GB0721095D0 (en) * | 2007-10-26 | 2007-12-05 | Piramed Ltd | Pharmaceutical compounds |
| AU2009276339B2 (en) | 2008-07-31 | 2012-06-07 | Genentech, Inc. | Pyrimidine compounds, compositions and methods of use |
| EP2346499A1 (en) | 2008-10-01 | 2011-07-27 | Novartis AG | Smoothened antagonism for the treatment of hedgehog pathway-related disorders |
| TWI378933B (en) | 2008-10-14 | 2012-12-11 | Daiichi Sankyo Co Ltd | Morpholinopurine derivatives |
| HRP20150947T1 (hr) | 2009-01-08 | 2015-10-09 | Curis, Inc. | Inhibitori fosfoinositid 3-kinaze sa skupinom koja veže cink |
| SG175708A1 (en) | 2009-05-27 | 2011-12-29 | Genentech Inc | Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| SG182247A1 (en) | 2009-05-27 | 2012-08-30 | Hoffmann La Roche | Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use |
| KR102050712B1 (ko) | 2009-06-17 | 2019-12-02 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제의 억제제 |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| MX2012002059A (es) | 2009-08-20 | 2012-04-19 | Karus Therapeutics Ltd | Compestos heterociclicos triciclicos como inhibidores de fosfoionositida 3-quinasa. |
| CN102711766B (zh) | 2009-11-12 | 2014-06-04 | 霍夫曼-拉罗奇有限公司 | N-9-取代的嘌呤化合物、组合物和使用方法 |
| US8828990B2 (en) | 2009-11-12 | 2014-09-09 | Genentech, Inc. | N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use |
| AU2011343712B2 (en) | 2010-12-16 | 2015-09-17 | Genentech, Inc. | Tricyclic PI3k inhibitor compounds and methods of use |
| UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
| GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
| CN104350144B (zh) | 2012-05-23 | 2017-08-04 | 弗·哈夫曼-拉罗切有限公司 | 获得和使用内胚层和肝细胞的组合物和方法 |
| WO2014068070A1 (en) | 2012-10-31 | 2014-05-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for preventing antiphospholipid syndrome (aps) |
| EP2917202B1 (en) | 2012-11-07 | 2018-05-02 | Karus Therapeutics Limited | Novel histone deacetylase inhibitors and their use in therapy |
| CA2911856A1 (en) | 2013-05-10 | 2014-11-13 | Karus Therapeutics Ltd | Tri-substituted amino hydroxamate compounds and pharmaceutical compositions thereof for use as histone deacetylase inhibitors |
| US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
| PL3068776T3 (pl) | 2013-11-13 | 2019-10-31 | Vertex Pharma | Inhibitory replikacji wirusów grypy |
| KR102338461B1 (ko) | 2013-11-13 | 2021-12-13 | 버텍스 파마슈티칼스 인코포레이티드 | 인플루엔자 바이러스 복제 억제제의 제조 방법 |
| GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
| GB201419264D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| GB201419228D0 (en) | 2014-10-29 | 2014-12-10 | Karus Therapeutics Ltd | Compounds |
| SG11201702162PA (en) * | 2014-12-11 | 2017-04-27 | Natco Pharma Ltd | 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs |
| WO2016147543A1 (en) | 2015-03-13 | 2016-09-22 | Ricoh Company, Ltd. | Electrochromic compound, electrochromic composition, electrochromic element, and electrochromic dimming element |
| MA42422A (fr) | 2015-05-13 | 2018-05-23 | Vertex Pharma | Inhibiteurs de la réplication des virus de la grippe |
| EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
| GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
| GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
| US10562849B2 (en) | 2016-05-16 | 2020-02-18 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
| US20240199637A1 (en) * | 2021-04-21 | 2024-06-20 | Natco Pharma Limited | Improved process for the preparation of 7-(morpholinyl)-2-(n-piperazinyl)methylthieno[2, 3-c]pyridine derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2356886T3 (es) | 1998-03-31 | 2011-04-14 | Kyowa Hakko Kirin Co., Ltd. | Compuestos heterocíclicos nitrogenados. |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| KR100774855B1 (ko) * | 2000-04-27 | 2007-11-08 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 헤테로아릴 유도체 |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| PL2041139T3 (pl) | 2006-04-26 | 2012-05-31 | Hoffmann La Roche | Związki farmaceutyczne |
-
2007
- 2007-04-25 RU RU2008141356/04A patent/RU2008141356A/ru not_active Application Discontinuation
- 2007-04-25 EP EP07732542A patent/EP2032582A1/en not_active Withdrawn
- 2007-04-25 AU AU2007242594A patent/AU2007242594A1/en not_active Abandoned
- 2007-04-25 US US12/298,507 patent/US8252792B2/en not_active Expired - Fee Related
- 2007-04-25 MX MX2008013582A patent/MX2008013582A/es not_active Application Discontinuation
- 2007-04-25 CA CA002650196A patent/CA2650196A1/en not_active Abandoned
- 2007-04-25 WO PCT/GB2007/001504 patent/WO2007122410A1/en not_active Ceased
- 2007-04-25 JP JP2009507152A patent/JP5302186B2/ja not_active Expired - Fee Related
- 2007-04-25 BR BRPI0710866-4A patent/BRPI0710866A2/pt not_active Application Discontinuation
- 2007-04-25 KR KR1020087028890A patent/KR20090021155A/ko not_active Withdrawn
-
2008
- 2008-10-15 CR CR10369A patent/CR10369A/es not_active Application Discontinuation
- 2008-10-22 IL IL194755A patent/IL194755A0/en unknown
- 2008-10-27 MA MA31338A patent/MA30360B1/fr unknown
- 2008-11-05 EC EC2008008867A patent/ECSP088867A/es unknown
- 2008-11-18 NO NO20084832A patent/NO20084832L/no not_active Application Discontinuation
-
2012
- 2012-07-19 US US13/553,650 patent/US8697693B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0710866A2 (pt) | 2012-08-14 |
| AU2007242594A1 (en) | 2007-11-01 |
| MA30360B1 (fr) | 2009-04-01 |
| EP2032582A1 (en) | 2009-03-11 |
| RU2008141356A (ru) | 2010-06-10 |
| KR20090021155A (ko) | 2009-02-27 |
| WO2007122410A1 (en) | 2007-11-01 |
| ECSP088867A (es) | 2008-12-30 |
| US20100016306A1 (en) | 2010-01-21 |
| JP2009534453A (ja) | 2009-09-24 |
| MX2008013582A (es) | 2009-01-19 |
| CA2650196A1 (en) | 2007-11-01 |
| IL194755A0 (en) | 2009-08-03 |
| JP5302186B2 (ja) | 2013-10-02 |
| US8697693B2 (en) | 2014-04-15 |
| US8252792B2 (en) | 2012-08-28 |
| US20120283257A1 (en) | 2012-11-08 |
| CR10369A (es) | 2009-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20084832L (no) | Pyrimidinderivater som P13K-inhibitorer | |
| NO20072115L (no) | Farmasoytiske forbindelser | |
| AU2008274670B2 (en) | Pyridazinone derivates | |
| KR20210040368A (ko) | 사이클린 의존성 키나제의 억제제 | |
| PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
| AU2014211856B2 (en) | Substituted 2-aminopyridine protein kinase inhibitor | |
| CA3172387A1 (en) | Indazole based compounds and associated methods of use | |
| HRP20140252T1 (hr) | Derivati imidazola kao inhibitori kazeinske kinaze | |
| MX2009008465A (es) | Nuevas 2-aminooxazolinas como ligandos de taar1. | |
| NO20073926L (no) | Pyrazolforbindelser som modulerer aktivitet av CDK-, GSK- og aurorakinaser | |
| MX2013010140A (es) | Amino-quinolinas como inhibidores de cinasa. | |
| WO2013089212A1 (ja) | 置換トリアジン誘導体およびそれらを含有する医薬組成物 | |
| PE20080772A1 (es) | Nuevos derivados de bipiridina sustituidos y su uso | |
| WO2014145015A2 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| MX2014006210A (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
| MX2009010884A (es) | 2-morfolin-4-il-pirimidinas como inhibidores de fosfatidilinositol-3-cinasa (pi3k). | |
| JP2009510086A5 (no) | ||
| AR061656A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, composicion farmaceutica que lo comprende y procesos para la preparacion de la composicion y del compuesto | |
| WO2013066831A1 (en) | Compounds and methods | |
| NO20074311L (no) | Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet | |
| NO20072409L (no) | Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser | |
| CA2827072A1 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
| TR200102789T2 (tr) | Cns bozukluklarının tedavisi için 1-Arensülfonil-2-aril-pirolidin ve piperidin türevleri | |
| IL301568A (en) | Protein alpha kinase 1 inhibitors and methods of use | |
| MX2009006636A (es) | Nuevos intermediarios y procesos utiles en la rpeparacion de {2-[1-(3,5-bis-trifluorometil-bencil)-5-piridin-4-il-1h-[1,2,3]tr iazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |